Hendi Susanto's questions to CTS Corp (CTS) leadership • Q2 2025
Question
Hendi Susanto of Gabelli Funds sought deeper insights into the medical market's mix, asking about the sustainability of large therapeutic orders and the expected duration of diagnostic softness. He also requested historical revenue for SciQuest, clarification on the size of the China transportation business, and details on the specific products driving the transportation pipeline.
Answer
CEO Kieran O’Sullivan projected the diagnostic softness could last another one to two quarters but affirmed long-term confidence, while therapeutic growth is expected to continue through 2025. CFO Ashish Agrawal declined to provide pre-acquisition revenue for SciQuest but noted that China's transportation revenue as a percentage of total sales is similar to the overall transportation segment's mix, referencing the prior year's total China revenue of over $80 million from the 10-K. Mr. O'Sullivan highlighted accelerator modules, passive safety sensors, and motor position sensing as key products in the transportation pipeline, noting the largest opportunities are in North America.